Poland· PL-100459990
Ronapreve
A casirivimab and imdevimab product containing casirivimabum + imdevimabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Casirivimab and imdevimab is registered in 5 of 19 countries.
Countries holding a registration under ATC J06BD07 (casirivimab and imdevimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Casirivimab and imdevimab · ATC J06BD07
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Polandprice
- Spainprice
The record
At a glance
URPL (Poland)- Active substance
- Casirivimabum + Imdevimabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- J06BD07
- ATC class
- Casirivimab and imdevimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin07613326052658
- gtin07613326052740
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Casirivimab and imdevimab in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/10b53b5c-6953-4b1a-bd16-80829fa2e327 GET /v1/drugs/10b53b5c-6953-4b1a-bd16-80829fa2e327?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań i infuzji",
"source": "urpl",
"strength": "120 mg/ml + 120 mg/ml",
"packaging": "07613326052658 ¦ Rp ¦ EU/1/21/1601/002 ¦ 142399\n1 fiol. 11,1 ml roztworu kazyrywymabu ¦ 1 fiol. 11,1 ml roztworu imdewymabu\n07613326052740 ¦ Rp ¦ EU/1/21/1601/001 ¦ 142482\n1 fiol. 2,5 ml roztworu kazyrywymabu ¦ 1 fiol. 2,5 ml roztworu imdewymabu",
"substance": "Casirivimabum 120 mg/ml + Imdevimabum 120 mg/ml",
"common_name": "Casirivimabum + Imdevimabum",
"pl_product_id": "100459990",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about casirivimab and imdevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.